+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma

The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma

Survey of Ophthalmology 41 Suppl 2: S111-S115

The use of beta blockers for glaucoma treatment may cause serious bronchoconstriction in patients with chronic obstructive pulmonary disease. The synthetic prostaglandin (PG) F2 alpha-analogue latanoprost (13,14,dihydro-17-phenyl-18,19,20-trinor-PGF-2-alpha-iso propylester) represents a new class of drugs for glaucoma treatment. In this study the pulmonary tolerability to latanoprost in 12 healthy volunteers and 11 (one withdrawal due to a sty before latanoprost treatment) subjects with moderate but stable steroid-treated intrinsic asthma was examined. Asthmatic subjects received 30 microliters of vehicle (placebo) at the scheduled administration times on baseline day. On a second day, a minimum of one week later, increasing concentrations (0.35, 115 and 350 micrograms/ml) of latanoprost were added to the vehicle and given topically to both eyes. Healthy volunteers were given latanoprost only. ECG, blood pressure, heart rate, forced expiratory volume (FEV1), peak expiratory outflow (PEF) and forced vital capacity (FVC) were recorded immediately prior to and 15, 30, 45 and 60 minutes after latanoprost. Asthmatic patients inhaled salbutamol (0.2 mg) at 60 minutes after the highest latanoprost dose. There were no significant differences in pulmonary function, blood pressure or heart rate after latanoprost in the healthy volunteers. Moreover, all parameters were unaffected in asthmatic patients on the day latanoprost was given compared to the baseline day. Latanoprost did not dampen the bronchodilator response to beta-2-adrenergic stimulation. It is concluded that latanoprost did not affect lung function in healthy subjects or in asthmatics after a total accumulated dose 10 times that clinically recommended for glaucoma treatment. Therefore, latanoprost appears to be safe for glaucoma treatment in patients with steroid-treated stable moderate intrinsic asthma.

(PDF emailed within 0-6 h: $19.90)

Accession: 033856713

Download citation: RISBibTeXText

PMID: 9154286

DOI: 10.1016/s0039-6257(97)80017-3

Related references

Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Current Medical Research and Opinion 20(9): 1341-1345, 2004

The mechanism for the additive ocular hypotensive effects of pilocarpine and latanoprost in ocular hypertensive human eyes. IOVS 40(4): S394, March 15, 1999

Ocular hypotensive effect of pilocarpine in latanoprost treated eyes; a pilot study. Archivos de la Sociedad Espanola de Oftalmologia 75(11): 735-740, 2001

Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Advances in Therapy 24(2): 302-309, 2007

Additive effects of latanoprost on ocular hypotensive regimens that include pilocarpine. IOVS 39(4): S199, March 15, 1998

Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Archives of Ophthalmology 115(7): 857-861, 1997

The ocular hypotensive effect of latanoprost in normal pressure glaucoma patients. Investigative Ophthalmology & Visual Science 36(4): S739, 1995

Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. Japanese Journal of Ophthalmology 54(4): 286-290, 2010

Additive ocular hypotensive effect of latanoprost and unoprostone in patients with open angle glaucoma. IOVS 42(4): S819, March 15, 2001

Efficacy and safety of the ocular Hypotensive LipidTM AGN 192024 in patients with elevated IOP A 30-day comparison with latanoprost. IOVS 41(4): S514, March 15, 2000

The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients. Journal of Glaucoma 20(4): 240-243, 2011

Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension. Journal of Ocular Pharmacology and Therapeutics 19(3): 193-203, 2003

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clinical Ophthalmology 4(): 1253-1261, 2010

Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology 104(9): 1503-1507, 1997

Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clinical Therapeutics 26(1): 84-91, 2004